Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial

FILE PHOTO: A vial labelled "Sinopharm COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration

COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.

Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.